A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

October 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

TQB2916 Injection

A Phase II clinical study to evaluate the efficacy and safety of TQB2916 injection combined with gemcitabine and albumin-paclitaxel as first-line treatment for metastatic pancreatic cancer.

DRUG

Chemotherapy

Chemotherapy is a systematic treatment.Chemotherapy drugs go into the body orally or intravenously, and they circulate throughout the body, and because of that, they can be used for advanced cancer, and they can also be effective against metastasized cancer cells.There are many chemotherapeutics, but the underlying mechanism is to kill fast growing cells.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY

NCT06962267 - A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type) | Biotech Hunter | Biotech Hunter